Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Lung Cancer. 2016 Jun 14;99:17–22. doi: 10.1016/j.lungcan.2016.06.006

Figure 2. ALK kinase domain mutations in different NSCLC cohorts.

Figure 2

A. Frequencies of ALK genomic changes and graphic representation of the ALK protein with ALK mutations identified in the TCGA 2014 lung adenocarcinoma cohort indicated. B. ALK rearrangements and ALK kinase domain mutations identified in the BIDMC NSCLC tumor-pair cohort. C. Tabulated ALK rearranged NSCLC cohort and percentage (%) of ALK kinase domain mutations in TKI-naïve and crizotinib-resistant biopsies. References to the original publication of the cohort are indicated in parenthesis. * We assumed that crizotinib-resistant samples with wild-type (WT) ALK kinase domain would also have lacked a mutation in the TKI-naïve setting and we excluded cases that had ALK kinase mutations in the crizotinib-resistant setting but were not analyzed in the TKI-naïve biopsy.